Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.

Trottier, Benoît; Lake, Jordan E; Logue, Ken; Brinson, Cynthia; Santiago, Lizette; Brennan, Clare; Koteff, Justin A; Wynne, Brian; Hopking, Judy; Granier, Catherine; Aboud, Michael

Trottier, Benoît; Lake, Jordan E; Logue, Ken; Brinson, Cynthia; Santiago, Lizette; Brennan, Clare; Koteff, Justin A; Wynne, Brian; Hopking, Judy; Granier, Catherine; Aboud, Michael.

Afiliación

Trottier B; Clinique medicale l'Actuel, Montreal, QC, Canada.
Lake JE; UCLA Clinical AIDS Research and Education Center, University of California, Los Angeles, CA, USA.
Logue K; CascAIDS Research, Toronto, ON, Canada.
Brinson C; Central Texas Clinical Research, Austin, TX, USA.
Santiago L; Hope Clinical Research, San Juan, Puerto Rico.
Brennan C; ViiV Healthcare, Research Triangle Park, NC, USA.
Koteff JA; ViiV Healthcare, Research Triangle Park, NC, USA.
Wynne B; ViiV Healthcare, Collegeville, PA, USA.
Hopking J; GlaxoSmithKline, Stockley Park, UK.
Granier C; GlaxoSmithKline, Stockley Park, UK.
Aboud M; ViiV Healthcare, Brentford, UK.

Antivir Ther ; 22(5): 459-460, 2017.

Article en En | MEDLINE | ID: mdl-28901945

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Antivir Ther Asunto de la revista: TERAPIA POR MEDICAMENTOS / VIROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google